| Hint | Answer | % Correct |
|---|---|---|
| what are examples of each? | insulin | 100%
|
| what are the treatment options for diabetes? | insulin and insulin analogues | 100%
|
| what is Type 1 diabetes? | insulin-dependent (absolute deficiency of insulin caused by an autoimmune condition) | 42%
|
| insulin secretagogues (sulfonylureas & meglitinides) | 33%
| |
| what is the biochemical function of insulin? | to trigger the absorption of glucose from the blood into the liver, skeletal muscle and fat tissue | 33%
|
| what are their mechanisms of action? | triggers the absorption of glucose from the blood into the liver, skeletal muscle and fat tissue | 33%
|
| improve the response of target cells to insulin by either:- decreasing hepatic gluconeogenesis & reducing intestinal absorption of sugars (biguanides) or: - activation of peroxisome proliferator-activated receptors (thiazolidinediones) | 25%
| |
| insulin sensitisers (biguanides & thiazolidinediones) | 25%
| |
| what is Type 2 diabetes? | non-insulin-dependent (decreased ability of tissues to respond to normal levels of insulin) | 25%
|
| promote insulin release from the b-cells of the pancreas by:- binding to and close ATP-sensitive K+ channels on b-cells - depolarising the cells and opens Ca2+ channels - triggering fusion of insulin granules with cell membrane | 25%
| |
| what is the biochemical function of glucagon? | to trigger the release of glucose into the blood from the liver via gluconeogenesis and glycogenolysis | 25%
|
| dyslipidaemia | 17%
| |
| what are the biochemical features of Type 2 diabetes? | hyperglycaemia | 17%
|
| what are the biochemical features of Type 1 diabetes? | hyperglycaemia and ketoacidosis | 17%
|
| hypertriacylglycerolaemia | 17%
| |
| oral hypoglycemic drugs | 17%
| |
| acarbose, miglitol, voglibose | 8%
| |
| a-glucosidase inhibitors | 8%
| |
| gastrointestinal hormones | 8%
| |
| competitively inhibit the action of the enzyme a-glucosidase, that breaks carbohydrates into monosaccharides | 0%
| |
| glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), peptide YY (PYY) | 0%
|